Skip Navigation


NDT Advance Access originally published online on February 16, 2007
Nephrology Dialysis Transplantation 2007 22(4):1013-1019; doi:10.1093/ndt/gfl844
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/4/1013    most recent
gfl844v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stassen, P. M.
Right arrow Articles by Stegeman, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stassen, P. M.
Right arrow Articles by Stegeman, C. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Use of mycophenolic acid in non-transplant renal diseases

Patricia M. Stassen1, Cees G. M. Kallenberg2 and Coen A. Stegeman1

1Department of Nephrology and 2Department of Clinical Immunology, University Medical Center Groningen, University of Groningen, The Netherlands

Correspondence and offprint requests to: Patricia M. Stassen, MD, Department of Nephrology, University Medical Center Groningen, PO box 30001, 9700 RB Groningen, The Netherlands. Email: pstassen@home.nl

Keywords: enteric-coated mycophenolate sodium; mycophenolate mofetil; mycophenolic acid; renal disease; review; treatment

The first 150 words of the full text of this article appear below.



   Introduction
 
Mycophenolic acid (MPA) is a relatively new immunosuppressive drug, used since the nineties for the prevention of rejection in kidney transplantation. MPA has not only proved effective in preventing rejection, being even superior to azathioprine, but also seems to cause less adverse effects than other immunosuppressive drugs [1]. Because of these favourable experiences with MPA in renal transplantation, the drug is currently used in patients with liver, lung and bone marrow transplantation as well. Given its favourable profile, MPA has also been used in autoimmune diseases. Following many cases and open series on the successful use of MPA, mostly in the form of mycophenolate mofetil (MMF), in renal, rheumatological, gastrointestinal, ophthalmological, dermatological and neurological autoimmune diseases, the first controlled studies have been published or are underway.

MPA is the active metabolite of the two currently available formulations: mycophenolate mofetil (MMF, Cellcept®) and the slow release formulation enteric-coated mycophenolate . . . [Full Text of this Article]



   MPA in proliferative lupus nephritis
 


   Membranous lupus nephritis
 


   IgA nephropathy
 


   Idiopathic (or primary) membranous glomerulopathy
 


   Minimal change nephropathy
 


   Focal segmental glomerulosclerosis
 


   Other renal diseases
 


   ANCA associated vasculitis
 


   Other forms of vasculitis
 


   Goodpasture's syndrome
 


   Adverse effects
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?